Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

• ≥ 18 years of age, but ≤70 years of age;
• IIEF EF Domain*1 score ≥ 22;
• be able to effectively communicate with study personnel;
• be considered by the physician to be available for subsequent visits;
• be willing to comply with all aspects of the treatment and evaluation schedule over a 24 month duration;
• sign and date an IRB-approved written informed consent prior to initiation of any study procedures, including screening procedures; and
• require radical prostatectomy.

Exclusion Criteria:

• prior surgery in the last 6 months which could affect sexual function;
• history of Peyronie's disease;
• significant neurological disorder (i.e. multiple sclerosis, peripheral neuropathy);
• treatment for major psychiatric disorders;
• history of penile implant or prosthesis;
• history of diabetic neuropathy;
• life expectancy of less than two years;
• concurrently involved in another investigational study;
• uncontrolled hypertension with systolic BP >200mmHg or diastolic BP >115mmHg is present at screening;
• currently receiving or planned treatment with chemotherapy or radiation therapy;
• diagnosis of bony metastasis;
• known allergy or severe intolerance to PDE-5 inhibitors; or
• cardiac pacing equipment or other electro-mechanical devices which preclude the use of CaverMap™ neurostimulator.